Business
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Myriad
About this update from Myriad Genetics, Inc.
[{"type":"text","content":"100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test\nSALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced MyRisk® Hereditary Cancer Test—the gold standard in germline testing—has been expanded to include genes referenced in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1 and guidelines from American Society of Clinical Oncology (ASCO). These genes are strongly associated with cancer risk and may have clear clinical actionability, supporting the goal that each addition to the panel provides meaningful insights for patient care. The updated MyRisk panel now includes 63 carefully selected genes across more than 11 cancer types, reflecting Myriad’s commitment to meeting evolving clinical needs. “While many labs can detect DNA variants, it’s the interpretation of those variants that truly impacts patient care and that is where Myriad excels,” said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics. “Medical societies recommend genes for testing when they influence treatment decisions, and those are the genes we prioritize in the MyRisk Test. I’m delighted that these clinically significant genes are now part of the core MyRisk panel. As guidelines evolve, Myriad remains committed to providing clinicians and genetic counselors with insights of high clinical utility to guide patient care.” The MyRisk Test is designed to deliver clinical value at every step of the cancer care continuum by helping treatment decisions, surveillance planning, and family risk assessment across multiple cancer types. Clinicians can conveniently order, receive, and review expanded MyRisk Test results directly through paper Test Requisition Forms and reports, the Myriad patient portal and several electronic medical record platforms, including EPIC and OncoEMR. To view the full gene list and associated medical management recommendations, please visit the Myriad gene table. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. About Myriad Genetics Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health ...